GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCC) » Definitions » Asset Turnover

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Cyclacel Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Cyclacel Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.03 Mil. Cyclacel Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $10.65 Mil. Therefore, Cyclacel Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Cyclacel Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 was -859.87%. It is also linked to ROA % through Du Pont Formula. Cyclacel Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was -197.95%.


Cyclacel Pharmaceuticals Asset Turnover Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Asset Turnover Chart

Cyclacel Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.02

Cyclacel Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.02 - -

Competitive Comparison of Cyclacel Pharmaceuticals's Asset Turnover

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclacel Pharmaceuticals's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's Asset Turnover falls into.



Cyclacel Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Cyclacel Pharmaceuticals's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.42/( (28.05+8.805)/ 2 )
=0.42/18.4275
=0.02

Cyclacel Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0.031/( (12.497+8.805)/ 2 )
=0.031/10.651
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Cyclacel Pharmaceuticals  (NAS:CYCC) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Cyclacel Pharmaceuticals's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-21.084/2.452
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-21.084 / 0.124)*(0.124 / 10.651)*(10.651/ 2.452)
=Net Margin %*Asset Turnover*Equity Multiplier
=-17003.23 %*0.0116*4.3438
=ROA %*Equity Multiplier
=-197.95 %*4.3438
=-859.87 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Cyclacel Pharmaceuticals's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-21.084/10.651
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-21.084 / 0.124)*(0.124 / 10.651)
=Net Margin %*Asset Turnover
=-17003.23 %*0.0116
=-197.95 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Cyclacel Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Executives
Spiro Rombotis director, officer: President & C.E.O. C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Paul Mcbarron director, officer: E.V.P., Finance & C.O.O. C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Kenneth M. Ferguson director 2125 1ST AVENUE #2902, SEATTLE WA 98121-2121
Sam L Barker director 51 AUNT MOLLY ROAD, HOPEWELL NJ 08525
Brian Schwartz director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Karin L Walker director C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Mark Kirschbaum officer: Chief Medical Officer 66 WEST 38TH STREET, APT. 19D, NEW YORK NY 10018
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Eastern Capital Ltd 10 percent owner 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Portfolio Services Ltd. 10 percent owner 10 MARKET STREET, # 773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kenneth Bryan Dart 10 percent owner P. O. BOX 31300, GRAND CAYMAN E9 KY1-1206
Lloyd Sems director C/O SEMS CAPITAL, 7 DEY STREET, SUITE 1101, NEW YORK NY 10017

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Headlines